ARG
Neuroendocrine Tumor Grade 1
David BushnellSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Neuroendocrine Tumor Grade 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus AC Camargo Cancer Center | Phase 2 | B |
LYSINE David Bushnell | Early Phase 1 | C |
[212pb] vmt-α-net David Bushnell | Early Phase 1 | C |
Same molecule, other indications
ARG is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →